Puma Biotechnology, Inc. (PBYI) financial statements and ratios from SEC XBRL: revenue $228.37M (TTM), net margin 13.6%, revenue growth 7.8% YoY, P/E 17.9. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $228.37M |
| Net Margin | 13.6% |
| Revenue Growth (YoY) | 7.8% |
| EPS Growth (YoY) | 33.3% |
| FCF Growth (YoY) | -88.5% |
| P/E Ratio | 17.9 |
| EV / EBITDA | 10.1 |
| Price / Book | 3.44 |
| Price / Sales | 2.06 |
| FCF Yield | 8.6% |
| DCF Value (model) | $14.39 |
| DCF Upside vs Price | 55.7% |
| Altman Z-Score | -2.95 (distress) |
| Piotroski F-Score | 7/9 |
| Sector P/E (Healthcare) | 21.7 |
PBYI overview · PBYI earnings · PBYI KPIs · PBYI investor relations · PBYI ownership · PBYI peers · PBYI filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.